Drugs - Xagena.net - Update in Medicine

Search results for "Rituximab"

Imbruvica plus Rituximab approved by FDA as first chemotherapy-free combination treatment in adults with Waldenström's macroglobulinemia

The U.S. Food and Drug Administration ( FDA ) has approved Imbruvica ( Ibrutinib ) plus Rituximab ( Rituxan ) for the treatment of adult patients with Waldenström's macroglobulinemia ( WM ), a rare an ... read article

Treatment of patients with untreated acute myeloid leukemia who are ineligible to receive standard induction therapy: Venetoclax receives Breakthrough Therapy designation from FDA

The Food and Drug Administration ( FDA ) has granted Breakthrough Therapy designation for the investigational agent Venetoclax in combination with hypomethylating agents ( HMAs ) for the treatment of ... read article

Chronic lymphocytic leukaemia, screen for hepatitis B virus before treatment with Ofatumumab

Ofatumumab ( Arzerra ) is indicated for the treatment of chronic lymphocytic leukaemia in patients who are refractory to Fludarabine and Alemtuzumab. Ofatumumab is a monocolonal antibody that acts ag ... read article

The FDA ( Food and Drug Administration ) has approved Rituxan ( Rituximab; in Europe: MabThera ), in combination with glucocorticoids ( steroids ), to treat patients with Wegeners granulomatosis and ... read article

NICE does not recommend Ofatumumab as a treatment for refractory chronic lymphocytic leukaemia

The NICE ( National Institute for Health and Clinical Excellence ) has published three separate pieces of guidance for the NHS ( National Health Service ) on the use of the cancer drugs Ofatumumab ( A ... read article

Rituximab reduces inflammation in patients with lupus nephritis

Treatment with Rituximab can significantly benefit some patients with severe lupus nephritis who do not respond to conventional therapy, according to a study published in the Clinical Journal of the A ... read article

Maintenance Rituximab is useful for advanced indolent lymphoma

A new study has found for the first time that maintenance therapy with the novel antibody, Rituximab ( MabThera, Rituxan ) following Cyclophosphamide, Vincristine and Prednisone ( CVP ) therapy improv ... read article

Immune thrombocytopenic purpura: Eltrombopag boosts platelets

Patients suffering from a blood disorder that prevents proper clotting have the option of a new medication that may dramatically improve their health. There are estimated to be between 50,000 and 100, ... read article

Rheumatoid arthritis: patients who fails to respond to initial treatment with Rituximab can still be successfully re-treated with a second course of drug

Rheumatoid arthritis patients who failed to respond to initial treatment with Rituximab ( MabThera, Rituxan ) ( a chimeric monoclonal antibody against the protein CD20 ) can still be successfully re-t ... read article

Graves' orbitopathy: Rituximab is effective after steroids fail

A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms and improved vision following treatment with the drug Rituximab MabThera, Rituxan ). Infla ... read article

Rheumatoid arthritis: Rituximab linked to progressive multifocal leukoencephalopathy

A third case of progressive multifocal leukoencephalopathy ( PML ) has been reported in a patient with rheumatoid arthritis treated with Rituxan ( Rituximab; MabThera ). This occurred in a 73-year old ... read article

Consolidation therapy following chemoimmunotherapy in B-cell chronic lymphocytic leukaemia: infection-related deaths reported with the use of MabCampath

Bayer HealthCare and Genzyme, in collaboration with Health Canada, informed of important safety information regarding the use of MabCampath ( Alemtuzumab ) as consolidation therapy following combinati ... read article

Multiple sclerosis: Rituximab shows promise

A drug therapy currently used to treat non-Hodgkins lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical t ... read article

Rituximab and Dexamethasone compared to Dexamethasone alone in idiopathic thrombocytopenic purpura

A phase III study is the first to prospectively determine that adding Rituximab ( MabThera, Rituxan ) to Dexamethasone is safe and effective in adult patients with previously untreated idiopathic thro ... read article

Rheumatoid arthritis: B cell depletion with anti-CD20

B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including rheumatoid arthritis ( RA ). In particular, B cell depletion wi ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article